Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuCD33 BsAb - Y-mAbs Therapeutics

Next Previous
Search
Drug Profile

HuCD33 BsAb - Y-mAbs Therapeutics

Alternative Names: huCD33-Bispecific antibody - Y-mAbs Therapeutics; huCD33-BsAb (CD33xCD3); huCD33-BsAb - Y-mAbs Therapeutics

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; CD33 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 31 Dec 2024 Suspended - Phase-I for Acute myeloid leukaemia (In adolescents, In children, Second-line therapy or greater, In adults) in USA (SC) before December 2024
  • 31 Dec 2024 Suspended - Preclinical for Haematological malignancies in USA (Parenteral) before December 2024
  • 25 May 2023 Y-mAbs Therapeutics terminates a phase I trial in Acute myeloid leukemia (In children, In adolescents, In adults, Second-line therapy or greater) in USA (SC), due to business priorities) (NCT05077423)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top